3SL9 image
Deposition Date 2011-06-24
Release Date 2012-02-29
Last Version Date 2023-09-13
Entry Detail
PDB ID:
3SL9
Title:
X-ray structure of Beta catenin in complex with Bcl9
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.24
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Catenin beta-1
Gene (Uniprot):CTNNB1
Chain IDs:A, C (auth: B), E, G
Chain Length:167
Number of Molecules:4
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:B-cell CLL/lymphoma 9 protein
Gene (Uniprot):BCL9
Chain IDs:B (auth: C), D, F, H
Chain Length:55
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
An intrinsically labile alpha-helix abutting the BCL9-binding site of beta-catenin is required for its inhibition by carnosic acid.
Nat Commun 3 680 680 (2012)
PMID: 22353711 DOI: 10.1038/ncomms1680

Abstact

Wnt/β-catenin signalling controls development and tissue homeostasis. Moreover, activated β-catenin can be oncogenic and, notably, drives colorectal cancer. Inhibiting oncogenic β-catenin has proven a formidable challenge. Here we design a screen for small-molecule inhibitors of β-catenin's binding to its cofactor BCL9, and discover five related natural compounds, including carnosic acid from rosemary, which attenuates transcriptional β-catenin outputs in colorectal cancer cells. Evidence from NMR and analytical ultracentrifugation demonstrates that the carnosic acid response requires an intrinsically labile α-helix (H1) amino-terminally abutting the BCL9-binding site in β-catenin. Similarly, in colorectal cancer cells with hyperactive β-catenin signalling, carnosic acid targets predominantly the transcriptionally active ('oncogenic') form of β-catenin for proteasomal degradation in an H1-dependent manner. Hence, H1 is an 'Achilles' Heel' of β-catenin, which can be exploited for destabilization of oncogenic β-catenin by small molecules, providing proof-of-principle for a new strategy for developing direct inhibitors of oncogenic β-catenin.

Legend

Protein

Chemical

Disease

Primary Citation of related structures